Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$614.16 USD
-4.30 (-0.70%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $613.90 -0.26 (-0.04%) 4:26 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$614.16 USD
-4.30 (-0.70%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $613.90 -0.26 (-0.04%) 4:26 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
3 MedTech Outperformers to Grab Amid Coronavirus Pandemic
by Trina Mukherjee
Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.
Henry Schein (HSIC) Enters Into New Dental Deal With Zyris
by Zacks Equity Research
Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) continues to gain traction from Senza, its flagship platform, and R&D capabilities. However, stiff competition remains a woe.
Varian's Halcyon System to Bring Improved Care to Singapore
by Zacks Equity Research
Varian (VAR) strengthens its partnership Proton Therapy Pte as it brings improved care to Singapore through Halcyon system.
NextGen Healthcare Introduces New Behavioral Health Suite
by Zacks Equity Research
NextGen Healthcare's (NXGN) new behavioral health suite aims to provide whole person care with support services for healthcare providers and clinicians.
Abbott Begins BTK Clinical Trial to Evaluate DRS Therapy
by Zacks Equity Research
Abbott (ABT) aims to provide a new treatment option for patients with CLI BTK, thus eliminating the need for any additional treatment.
Boston Scientific's Eluvia Gets CMS' Additional Reimbursement
by Zacks Equity Research
Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect dismal segmental performance. However, it exceeded expectation as it witnessed faster-than-anticipated recovery.
Aurora Cannabis (ACB) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal fourth-quarter results likely to reflect solid prospects in the Canadian market.
Patterson Companies (PDCO) Q1 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Despite weak performance across Patterson Companies' (PDCO) Dental and Animal Health segments in the fiscal first quarter results, it benefited from aggressive cost savings measures.
Bear of the Day: Illumina (ILMN)
by Madeleine Johnson
The coronavirus pandemic has dampened this medical stock's earnings and outlook.
Medtronic (MDT) Plans Up to $475M of Annual Cost Savings
by Zacks Equity Research
Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.
Is Thermo Fisher (TMO) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Thermo Fisher (TMO).
ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam
by Zacks Equity Research
ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.
Zacks.com featured highlights include: SGC, TMO, KR, WERN and ATVI
by Zacks Equity Research
Zacks.com featured highlights include: SGC, TMO, KR, WERN and ATVI
Phirbo's Product Mix Aids, Global Animal Health Business Ails
by Zacks Equity Research
Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.
Medtronic's Pediatric Diabetes Device Gets Regulatory Nod
by Zacks Equity Research
MiniMed 770G is Medtronic's (MDT) MiniMed 670G System's upgraded version.
OMRI Clears NEOGEN's AquaPrime Peraside 15 as USDA Compliant
by Zacks Equity Research
NEOGEN (NEOG) completes organic certified water treatment program with the latest certification.
Syneos Health-Idorsia Collaborate to Launch Daridorexant in US
by Zacks Equity Research
Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.